Gund Machhindra, Khanna Amit, Dubash Nauzer, Damre Anagha, Singh Kishore S, Satyam Apparao
Medicinal Chemistry Division, Piramal Enterprises Limited, 1-Nirlon Complex, Goregaon East, Mumbai 400063, India.
Bioorg Med Chem Lett. 2015 Jan 1;25(1):122-7. doi: 10.1016/j.bmcl.2014.10.088. Epub 2014 Nov 12.
A new series of disulfide-containing prodrugs of paclitaxel were designed, synthesized and evaluated against 6 cancer cell lines. Some of these prodrugs exhibited nearly equal or slightly better anticancer activity when compared to that of paclitaxel. These prodrugs contain water-soluble groups such as amino, carboxyl, hydroxyl, amino acids, etc., and exhibited 6-140 fold increase in aqueous solubility when compared to paclitaxel. One of these prodrugs exhibited improved water solubility, better in vitro anticancer activity and significantly superior oral bioavailability in mice when compared to those of paclitaxel. Thus, we have identified a very promising lead compound for further optimization and evaluation as a potentially bioavailable water-soluble prodrug of paclitaxel.
设计、合成了一系列新的含二硫键的紫杉醇前药,并针对6种癌细胞系进行了评估。与紫杉醇相比,其中一些前药表现出几乎相同或略好的抗癌活性。这些前药含有氨基、羧基、羟基、氨基酸等水溶性基团,与紫杉醇相比,其水溶性提高了6至140倍。其中一种前药与紫杉醇相比,表现出改善的水溶性、更好的体外抗癌活性以及在小鼠体内显著更高的口服生物利用度。因此,我们已经确定了一种非常有前景的先导化合物,可进一步优化和评估,作为紫杉醇潜在的生物可利用水溶性前药。